NIVF (NewGenIvf Group) EBIT: $9.52 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NIVF NewGenIvf Group Ltd NIVF
14 GF Score
Price $1.12
! 4 Warning Signs
View Full Analysis

What is NewGenIvf Group EBIT?

NewGenIvf Group NIVF -9.09% 14 EBIT is $9.52 Mil as of Dec. 2025. GuruFocus rates NIVF with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

NewGenIvf Group's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was $-7.27 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $9.52 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NewGenIvf Group's annualized ROC % for the quarter that ended in Dec. 2025 was -61.71%. NewGenIvf Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -650.04%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NewGenIvf Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 130.60%.

NewGenIvf Group  (NAS:NIVF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NewGenIvf Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-19.896 * ( 1 - 0% )/( (34.015 + 30.466)/ 2 )
=-19.896/32.2405
=-61.71 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=35.558 - 1.248 - ( 0.295 - max(0, 1.621 - 5.556+0.295))
=34.015

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=32.723 - 1.498 - ( 0.759 - max(0, 2.366 - 7.384+0.759))
=30.466

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

NewGenIvf Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-29.096/( ( (1.176 + max(1.632, 0)) + (2.293 + max(3.851, 0)) )/ 2 )
=-29.096/( ( 2.808 + 6.144 )/ 2 )
=-29.096/4.476
=-650.04 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.186 + 0.087 + 2.674) - (1.248 + 0.067 + 0)
=1.632

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.167 + 0.335 + 5.221) - (1.498 + 0.112 + 0.262)
=3.851

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NewGenIvf Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=9.522/7.291
=130.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewGenIvf Group EBIT Related Terms

NewGenIvf Group EBIT Historical Data

* Premium members only.

The historical data trend for NewGenIvf Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewGenIvf Group EBIT Chart

NewGenIvf Group Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
0.24 0.42 0.16 -0.18 10.35

NewGenIvf Group Quarterly Data
Dec21 Dec22 Jun23 Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only 0.21 -0.12 0.00 16.80 -7.27

NIVF vs RHEP, XCRT, SYRA: EBIT Comparison

For the Medical Care Facilities subindustry, NewGenIvf Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewGenIvf Group EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NewGenIvf Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NewGenIvf Group's EV-to-EBIT falls into.


NIVF
14GF Score
NewGenIvf Group Ltd NIVF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NewGenIvf Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $9.52 Mil mean?
NewGenIvf Group (NIVF) has a EBIT of $9.52 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NewGenIvf Group.
Is NewGenIvf Group's EBIT too high?
NewGenIvf Group's current EBIT is $9.52 Mil. Overall, NewGenIvf Group has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does NewGenIvf Group's EBIT compare to RHEP and XCRT?
NewGenIvf Group's EBIT of $9.52 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NewGenIvf Group. NewGenIvf Group's current EBIT is $9.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewGenIvf Group stock overvalued right now?
NewGenIvf Group (NIVF) has a current EBIT of $9.52 Mil. The current EBIT is $9.52 Mil. NewGenIvf Group's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For NewGenIvf Group (NIVF), the current EBIT is $9.52 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NewGenIvf Group Business Description

Address Sukhumvit 21 Road, Asoke, 36/39-36/40, 13th Floor, PS Tower, Khlong Toei Nuea Sub-district, Watthana District, Bangkok, THA, 10110
NewGenIvf Group Ltd is a tech-forward, diversified, multi-jurisdictional entity capitalizing on emerging opportunities across real estate development, digital asset innovation, and reproductive health solutions. The company offers two services, namely: in vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and fertility referral services, like surrogacy and ancillary caring services. It derives maximum revenue from in vitro fertilization (IVF) treatment service. Its Geographical presence is in China / HK SAR, Thailand, Cambodia, U.S and Kyrgyzstan. The company derives maximum revenue from Kyrgyzstan.
14GF Score

Get the complete analysis for NIVF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price